Article Information
vol. 7 no. 7, 799-809
- Published online June 27, 2014.
Author Information
- Shunmoogum A. Patten1,
- Gary A. B. Armstrong1,
- Alexandra Lissouba1,
- Edor Kabashi2,
- J. Alex Parker1 and
- Pierre Drapeau1,*
- 1Department of Neuroscience, FRQS Groupe de Recherche sur le Système Nerveux Central and CRCHUM, University of Montréal, Montréal, QC H3A 2B4, Canada.
- 2Institut du Cerveau et de la Moelle Épinière, Centre de Recherche, CHU Pitié-Salpétrière, 75013 Paris, France.
- ↵* Author for correspondence (p.drapeau{at}umontreal.ca)
Article usage
Usage statistics are calculated at the beginning of each month for the previous month.
Statistics from Altmetric.com
Article navigation
- Top
- Article
- Abstract
- Introduction
- Common pathological pathways between the different MNDs
- The zebrafish toolbox: how useful is it for studying MNDs?
- Zebrafish as a tool for drug screening
- Spinal muscular atrophy (SMA)
- Amyotrophic lateral sclerosis (ALS)
- Hereditary spastic paraplegia (HSP)
- Chemical screens in zebrafish models for other neural diseases
- Concluding remarks and perspectives
- Footnotes
- References
- Figures & tables
- Info & metrics
Related articles
Cited by...
More in this TOC section
Similar articles
Subject collections
Other journals from The Company of Biologists
First person — Andrew Scott Emmert and Eri Iwasawa
In an interview, first authors Andrew Scott Emmert and Eri Iwasawa discuss their new paper on impaired CSF flow and neural differentiation in a rat model of hydrocephalus, their research process and plans for the future.
Ethan Perlstein and colleagues present two back-to-back articles. In the first, they describe how the diabetic neuropathy drug palrestat can ameliorate PMM2-CDG. The second identifies the FDA-approved aripiprazole as a clinical candidate for treating NGLY1 deficiency.
Read Murgia et al.’s new resource article describing a SILAC-based proteomics approach to quantify the unfolded protein response.
We're excited to be an affiliate journal for Review Commons, the ASAPbio/EMBO platform for high-quality journal-independent peer-review in the life sciences, which went live on 09 December.